News
Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...
The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.
Novo Nordisk (NVO, Financials) shares climbed nearly 5% Monday after the U.S. Food and Drug Administration granted ...
Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...
Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the ...
Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...
An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...
Air Canada says it now plans to resume flights on Monday evening after a planned resumption of service on Sunday afternoon ...
Morning. Today, we examine the plush pay packages of health care’s top CEOs in 2024. Also, we discuss Stealth BioTherapeutics’ efforts to rally support behind its Barth syndrome drug, and hear more ...
Artificial intelligence could generate annual net benefits of roughly $920 billion for S&P 500 companies, according to Morgan Stanley (NYSE:MS).
Bernstein has upgraded Toyota (TYO:7203) (NYSE:TM) to Outperform from Market-Perform and raised its price target to 3,500 Japanese yen from ¥2,550 yen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results